Figure 3. HNF-6 is required for proper morphology of the neuromuscular junction.
Image credit: Audouard, et.al. 2012 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Arthur J. Hudson Translational Team Grant
Sponsor: ALS Canada
Description: This program aims to bring together researchers from across the country to accelerate therapeutic development by: 1) identifying and testing a relevant therapeutic target or candidate therapy and/or 2) addressing critical needs for early diagnosis and biomonitoring of clinical progression applied to clinical research. Research in all stages of development is welcomed, from basic/preclinical to phase I, II and III clinical trials. The award is up to $1.8 M CAD for 1 to 5 years. Qualifying teams will be composed of a minimum of three independent principal investigators in Canada from at least two different institutions.
Deadline: Letter of Intent due by March 17, 2017.



NEW! ALS Canada Trainee Program
Sponsor: ALS Canada
Description: The purpose of this grant program is nurture promising young investigators into a career focused on ALS research. A Clinical Research Fellowship would be funded at $100,000 CAD per year for up to two years. Each Postdoctoral Fellowship would be funded at $55,000 CAD per year for up to three years. Each Doctoral Award would be funded at $25,000 CAD per year for up to three years. Non-Canadians training in Canadian labs are eligible to apply for doctoral and postdoctoral fellowships.
Deadline: Application due by April 14, 2017.



NEW! ALS Canada Project Grant Program
Sponsor: ALS Canada
Description: The purpose of the program is to invest in the best possible projects in Canada that are i) novel research approaches, supported by sound rationale and a feasible experimental plan, but not necessarily preliminary data, ii) part of an ongoing ALS research program, and aimed toward the vision of ALS Canada that “By 2024, ALS is a treatable, not terminal disease” or iii) research focused on avenues to maximize function, minimize disability and optimize quality of life through symptom management, and support to families and persons or families living with ALS. Examples include, but are not limited to, management of secretions and cramps, psychological interventions to address mental health issues, nutritional interventions, respiratory care, engineering applications to reduce physical limitations, and programs to address the needs of caregivers. Up to eight awards of up to $125,000 CAD will be awarded for a duration 1-2 years.
Deadline: Application due by June 3, 2017.



MDA Venture Philanthropy Program
Sponsor: Muscular Dystrophy Association
Description: MDA’s MVP program is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. The diseases funded include ALS. MVP funds projects from proof-of-principle studies through phase 2 trials. The maximum award is  $1M USD for preclinical studies, $3M USD for early clinical studies and $500,000 USD for R&D.
Deadline: Letter of Intent due by March 1, 2017.



Multinational Research Projects for Pathway Analysis Across Neurodegenerative Diseases
Sponsor: EU Joint Programme – Neurodegenerative Disease Research (JPND)
Description: There is clinical, genetic and biochemical evidence that similar molecular pathways are relevant in different neurodegenerative and other chronic diseases. Therefore, clinical phenotypes alone seem insufficient to provide an understanding of the underlying mechanisms involved, and to be the sole basis for prognosis and diagnosis of neurodegenerative diseases. For this reason, JPND is launching a call for multidisciplinary multinational multi-institutional proposals to perform network analyses in different neurodegenerative and other chronic diseases to elucidate the underlying mechanisms involved. The combined analysis of diseases across traditional clinical boundaries, technologies and disciplines may lead to a re-definition of clinical phenotypes and new approaches in the treatment of neurodegenerative diseases. Projects can be funded for a period of up to three years with starting dates beginning as early as the end of 2017.
Deadline: Application due by March 6, 2017.



Target ALS Research Consortia
Sponsor: Target ALS Foundation
Description: This award is focused on bringing investigators (3-6 laboratories) together to work collaboratively on the discovery and validation of ALS therapeutic targets. The maximum award is $130,000 per year per lab. The total award is up to $650,000 per year.
Deadline: Application due by March 6, 2017.



Identify and Characterize Potential Environmental Risk Factors for ALS and Evaluate Their Impact on ALS Disease Incidence and Progression
Sponsor: Centers for Disease Control and Prevention
Description: The ATSDR is soliciting investigator-initiated research that will identify and characterize environmental toxicants in human biological samples that may be potential environmental risk factors for ALS. Applications are also sought that will evaluate the impact of environmental toxicants on the development and progression of ALS, including gene-environment interactions. The award is $350,000 to $500,000 USD.
Deadline: Application due by March 31, 2017.



Transformational Research 2017 (Canada)
Sponsor: Weston Brain Institute
Description: Provides funding (maximum of $1,500,000 over up to 3 years) for high-potential translational research projects with excellent preliminary data that will advance the development of therapeutics for neurodegenerative diseases of aging including frontotemporal dementia. Projects include the development of a therapeutic and/or a tool that helps to accelerate the development of therapies for these diseases. Research must take place at institutions that are Canada Revenue Agency qualified donees located in Canada. If your project is awarded, funds are provided in tranches when experimental milestones are successfully completed.
Deadline: Letter of Intent due by March 31, 2017.



UK: Novel Biomarkers 2017
Sponsor: Weston Brain Institute
Description: The UK: Novel Biomarkers program was launched to support high-risk, high-reward, translational research on novel biomarkers of neurodegenerative diseases of aging including frontotemporal dementia. The program funds testing of novel biomarkers in clinical samples/data or patients to accelerate the development of therapeutics for these diseases. Up to £333,000 over up to 3 years is available per project. Funds are provided contingent on meeting milestones. If your project is awarded, funds are provided in tranches when experimental milestones are successfully completed.
Deadline: Letter of Intent due by April 19, 2017.



Bioengineering Research Partnerships
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS) and National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Description: This Funding Opportunity Announcement (FOA) encourages bioengineering applications that will accelerate the development and adoption of promising tools and technologies that can address important biomedical problems.  The objectives are to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need and are capable of enhancing our understanding of life science processes or the practice of medicine.  Awards will focus on supporting multidisciplinary teams that apply an integrative, quantitative bioengineering approach to developing technologies, and engage biomedical researchers or clinicians throughout the project.  The goal of the program is to support projects that can realize meaningful solutions within 5 – 10 years.
Deadline: Application due by May 18, 2017.



Discovery Research Grants
Sponsor: Muscular Dystrophy Association
Description: Applications should focus on accelerating therapy development in neuromuscular diseases. The diseases funded include ALS. Such projects may include: (1) new target identification; (2) target validation; (3) screening for new therapeutic molecules that hit validated targets and (4) addressing a need in the field (e.g., developing a novel animal or cell model of the disease or developing new technologies). The award is $100,000 per year for 1 to 3 years.
Deadline: Letter of Intent due by June 15, 2017.



Judith and Jean Pape Adams ALS Research Grants
Sponsor: The Judith and Jean Pape Adams Foundation
Description: These grants support research that is aimed at discovering the causes of and finding a cure for ALS. The Foundation funds research that is innovative and aggressive. The research must be of high scientific merit. We encourage partnerships and collaborative efforts in proposing initiatives to fill gaps not currently being investigated and that involve novel approaches. The foundation will begin receiving applications in March 2017.
Deadline: Application due by August 11, 2017.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by September 30, 2017.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association. Applications received beginning September 8, 2017.
Deadline: Application due by November 3, 2017.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Healthcare Research Grants
Sponsor: Motor Neurone Disease Association (MNDA)
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.  
Deadline: Now accepting applications.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail